• AstraZeneca announces that it is resuming the trial of its experimental coronavirus vaccine in Britain, while trials in Brazil, South Africa and US remain on hold. The decision is based on a ruling from an independent investigation and supported by the Medicines and Healthcare Products Regulatory Agency; the company did not disclose any more details. Source
• Pfizer and BioNTech announce that they have amended the protocol for their phase III coronavirus vaccine trial, expanding it from 30,000 to 44,000 study volunteers, allowing them to increase diversity by enrolling adolescents (ages 16 and up), people with stable HIV, chronic hepatitis B virus and hepatitis C virus, noting that a “…conclusive readout on efficacy is likely by the end of October.” Source
